CR Double-Crane subsidiary secures clinical trial approval for Stargardt disease drug

China Resources Double-Crane Pharmaceutical announced that its subsidiary, Beijing Double-Crane Runchuang Technology Co., Ltd., has received a drug clinical trial approval notice from the National Medical Products Administration for DC6001 tablets. This drug is intended for the treatment of Stargardt disease, a hereditary macular degeneration affecting adolescents. The application was submitted on October 9, 2025, accepted on October 13, 2025, and the approval notice was issued on December 19, 2025.

The clinical trial application for DC6001 tablets was found to meet regulatory requirements for drug registration, thus allowing the commencement of clinical trials. The company has invested a cumulative research and development amount of RMB14.897m in this drug.

DC6001 tablets are currently in the early stages of clinical development, facing inherent risks regarding safety, efficacy, and quality control. The drug's eventual market launch depends on successful completion of clinical trials and regulatory approval. The company will actively advance this R&D project and provide timely updates on its progress.